JERUSALEM, Feb. 24, 2014 /PRNewswire/ -- BioLineRx
(NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical
company dedicated to identifying, in-licensing and developing
promising therapeutic candidates, announced today the appointment
of Sandra Panem, Ph.D., to its Board
of Directors.
(Logo: http://photos.prnewswire.com/prnh/20130730/630769)
Dr. Panem has had an extensive and impressive career in the
healthcare and life sciences industries in the U.S. Her experience
encompasses corporate and financial strategy, corporate governance,
venture capital, technology assessment, research management and
public policy. Dr. Panem is currently a Managing Partner at Cross
Atlantic Partners and serves on the Board of Directors of Acorda
Therapeutics, Inc. (NASDAQ: ACOR), GenomeQuest, Inc., Labcyte, Inc.
and MDx Medical (Vitals.com).
"We are thrilled to have Dr. Sandra
Panem join BioLineRx's Board," said Aharon Schwartz, Ph.D., Chairman of the Board of
BioLineRx. "Sandra brings to BioLineRx a unique track record in
healthcare strategy, technology assessment and capital markets
experience, and we expect that she will add great value to our
Company as we continue to accelerate the development of our
clinical and pre-clinical pipeline towards commercialization. We
also believe that her appointment to the Board, along with the
appointment of Dr. BJ Bormann in the second half of last year,
emphasizes BioLineRx's continued commitment to the US market."
Dr. Panem stated, "I am very excited to join the Board of
BioLineRx. I look forward to working with the Company to help guide
the strategy and development of its pipeline of exciting product
candidates. I am encouraged by the Company's strong track record of
identifying and vetting promising new compounds, and I plan to
leverage my expertise and relationships across the healthcare
industry in order to maximize the potential of these assets."
Dr. Panem has served on numerous Boards of public and private
companies, including Martek Biosciences (NASDAQ:MATK), IBAH
Pharmaceuticals (IBAH), Confluent Surgical and Molecular
Informatics. Her previous positions include President of Vector
Fund Management; Vice President and Portfolio Manager for the
Oppenheimer Global BioTech Fund, a mutual fund that invested in
public and private biotechnology companies; and Vice President at
Salomon Brothers Venture Capital, a fund focused on early and
later-stage life sciences and technology investments. She was also
a Science and Public Policy Fellow in economic studies at the
Brookings Institution, and an Assistant Professor of Pathology at
the University of Chicago. Dr. Panem
received a B.Sc. in Biochemistry and a Ph.D. in Microbiology from
the University of Chicago.
About BioLineRx
BioLineRx is a publicly-traded,
clinical-stage biopharmaceutical company dedicated to identifying,
in-licensing and developing promising therapeutic candidates. The
Company in-licenses novel compounds primarily from academic
institutions and biotech companies based in Israel, develops them through pre-clinical
and/or clinical stages, and then partners with pharmaceutical
companies for advanced clinical development and/or
commercialization.
BioLineRx's current portfolio consists of a variety of clinical
and pre-clinical projects, including: BL-1040 for prevention of
pathological cardiac remodeling following a myocardial infarction,
which has been out-licensed to Bellerophon BCM (f/k/a Ikaria) and
is in the midst of a pivotal CE-Mark registration trial; BL-8040
for treating acute myeloid leukemia (AML) and other hematological
indications, which is in the midst of a Phase 2 study; BL-7010 for
celiac disease, which is in the midst of a Phase 1/2 study; and
BL-5010 for non-surgical removal of skin lesions, which is expected
to commence a pivotal CE-mark registration trial in the first half
of 2014.
For more information on BioLineRx, please visit
www.biolinerx.com or download the investor relations mobile device
app, which allows users access to the Company's 'SEC documents,
press releases, and events. BioLineRx's' IR app is available on the
iTunes App Store as well as the
Google Play Store.
Various statements in this release concerning BioLineRx's
future expectations constitute "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements include words such as "may," "expects,"
"anticipates," "believes," and "intends," and describe opinions
about future events. These forward-looking statements involve known
and unknown risks and uncertainties that may cause the actual
results, performance or achievements of BioLineRx to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Some of
these risks are: changes in relationships with collaborators; the
impact of competitive products and technological changes; risks
relating to the development of new products; and the ability to
implement technological improvements. These and other factors are
more fully discussed in the "Risk Factors" section of BioLineRx's
most recent annual report on Form 20-F filed with the Securities
and Exchange Commission on March 12,
2013. In addition, any forward-looking statements represent
BioLineRx's views only as of the date of this release and should
not be relied upon as representing its views as of any subsequent
date. BioLineRx does not assume any obligation to update any
forward-looking statements unless required by law.
Contact:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.
jdrumm@tiberend.com
+1-212-375-2664
Andrew Mielach
amielach@tiberend.com
+1-212-375-2694
Or
Tsipi Haitovsky
Public Relations
+972-3-6240871
tsipihai5@gmail.com
SOURCE BioLineRx